Clinical Trials
19 trialsNCT04010357 2026-05-12
Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03643510 2026-03-16
Evaluating Cancer Response to Treatment With Abemaciclib and Fulvestrant in Women With Recurrent Endometrial Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT04603183 2025-12-12
ABIGAIL
MedSIR
Phase 2 Completed
NCT04352777 2025-07-20
Impact of Endocrine Therapy and Abemaciclib on Host and Tumor Immune Cell Repertoire/Function in Advanced ER+/HER2- Breast Cancer
Duke University
Phase 2 Completed
NCT04552769 2025-06-05
Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
Stanford University
Phase 2 Completed
NCT04432454 2025-02-13
ELAINEII
Sermonix Pharmaceuticals Inc.
Phase 2 Completed
NCT02675231 2024-11-26
monarcHER
Eli Lilly and Company
Phase 2 Completed
NCT04408924 2024-06-25
CYCLONE 1
Eli Lilly and Company
Phase 2 Completed
NCT03703466 2024-04-02
A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer
Eli Lilly and Company
Phase 2 Completed
NCT03339843 2024-03-15
MiMe-A
Jules Bordet Institute
Phase 2 Completed
NCT01739309 2023-09-21
Study of LY2835219 for Mantle Cell Lymphoma
Eli Lilly and Company
Phase 2 Completed
NCT03356223 2023-02-23
ABORL
Centre Leon Berard
Phase 2 Completed
NCT03292250 2022-03-29
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
Seoul National University Hospital
Phase 2 Completed
NCT02450539 2021-08-13
A Study of Abemaciclib (LY2835219) in Participants With Stage IV Squamous Non-small Cell Lung Cancer
Eli Lilly and Company
Phase 2 Completed
NCT02308020 2020-12-19
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
Eli Lilly and Company
Phase 2 Completed
NCT02441946 2020-06-17
neoMONARCH
Eli Lilly and Company
Phase 2 Completed
NCT02102490 2020-01-21
MONARCH 1
Eli Lilly and Company
Phase 2 Completed
NCT02981342 2019-11-20
A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma
Eli Lilly and Company
Phase 2 Completed
NCT02831530 2018-03-29
ABC-POP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed